共 50 条
Get to the point in intensive care medicine - the sooner the better?
被引:4
|作者:
Westphal, Martin
[1
,2
]
机构:
[1] Fresenius Kabi AG, D-61352 Bad Homburg, Germany
[2] Univ Hosp Muenster, Dept Anesthesiol Intens Care & Pain Med, D-48149 Munster, Germany
来源:
关键词:
RENAL-REPLACEMENT THERAPY;
CRITICALLY-ILL PATIENTS;
GOAL-DIRECTED THERAPY;
SEVERE SEPSIS;
SEPTIC SHOCK;
MECHANICAL VENTILATION;
SEDATION;
PROPOFOL;
MANAGEMENT;
MIDAZOLAM;
D O I:
10.1186/cc11506
中图分类号:
R4 [临床医学];
学科分类号:
1002 ;
100602 ;
摘要:
Timing of therapy plays a pivotal role in intensive care patients. Although being evident and self-explanatory, it has to be considered that the appropriateness of a specific therapeutic intervention is likewise important. In view of antibiotic therapy of critically ill patients, the available evidence supports the concept of hitting hard, early (as soon as possible and at least before the onset of shock) and appropriately. There is increasing evidence that a positive fluid balance is not only a cosmetic problem but is associated with increased morbidity. However, prospective studies are needed to elucidate whether a positive net fluid balance represents the cause or the effect of a specific disease. Since central venous pressure (CVP) is an unreliable marker of fluid responsiveness, its clinical use to guide fluid therapy is questionable. Dynamic hemodynamic parameters seem to be superior to CVP in predicting fluid responsiveness in hemodynamically unstable patients. Sedation is often used to facilitate mechanical ventilation. Since there is no best evidence-based sedation protocol, weaning strategies should take the risk of iatrogenic arterial hypotension secondary to high doses of vasodilatory sedative agents into account. In this regard, the concept of daily wake-up calls should be challenged, because higher cumulative doses of sedatives may be required. The right dose and timing for renal replacement therapy is still discussed controversially and remains a subjective decision of the attending physician. New renal biomarkers may perhaps be helpful to validate when (and how) renal replacement therapy should be performed best. Last but not least, all therapeutic interventions should take the individual co-morbidities and underlying pathophysiological conditions into account.
引用
收藏
页数:5
相关论文